RxDoctor Payments Data

Charles Kutler, MD

Infectious Disease · Kingston, NYNPI 1063464519

Payments from drug & device makers

$1,839in general payments, 2019–2025

Across 114 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$269
  • Organogenesis Inc.$225
  • Viiv Healthcare Company$199
  • AbbVie$194
  • Novo Nordisk$137
  • Misonix Inc$134
  • plus $680 from 17 others

What the payments were for

  • Food & beverage$1,839100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,839 in reported general payments places this provider in the 70th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$232,732
Medicare patients
323
Services billed
87,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala72$296,628
GenvoyaElviteg/Cob/Emtri/Tenof Alafen18$74,866
XifaxanRifaximin13$44,652
JulucaDolutegravir/Rilpivirine11$36,506
Fosfomycin Tromethamine38$10,728
ErtapenemErtapenem Sodium14$7,151
Daptomycin21$6,716
CeftriaxoneCeftriaxone Sodium47$6,325
Vancomycin Hcl28$2,318
Methenamine Hippurate11$1,665
Doxycycline Hyclate71$1,397
Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl19$1,082
Cephalexin12$889
CefuroximeCefuroxime Axetil40$535
Azithromycin47$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$96$371,49490 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$81$44,65213 claims
Viiv Healthcare CompanyJuluca$199$36,50611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 799 infectious disease providers in New York.

Other infectious disease in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →